Barrett Esophagus and Neoplasia

Use of proton-pump inhibitors was associated with diminished risk for high-grade dysplasia or esophageal adenocarcinoma.

Because Barrett esophagus is associated with excess risk for esophageal adenocarcinoma, one of the most common questions posed by patients with newly diagnosed BE is, “What can I do to prevent cancer?” Beyond providing endoscopic surveillance for detection of dysplasia, the possibility of using pharmacologic agents — proton-pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or statins — as an additive chemoprevention strategy has received much attention.

To assess the effects of such agents in this setting, investigators conducted a retrospective observational study involving 344 patients with BE (mean age, 61; 94.2% male; 90.4% white) from a cohort of patients who were described in a prior study (JW Gastroentero…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors